Vol. 4 No. 9 (2024)
Reimbursement Reviews

Tralokinumab (Adtralza)

decorative image of the issue cover

Published September 18, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses tralokinumab (Adtralza), 150 mg per 1 mL prefilled syringe and 300 mg per 2 mL prefilled pen,a solution for subcutaneous injection.
  • Indication: For the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable; tralokinumab can be used with or without topical corticosteroids.